NCT07320872 Correlation Between Vaspin Gene Polymorphism and Serum Vaspin Levels in Psoriasis Vulgaris
| NCT ID | NCT07320872 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Aswan University |
| Condition | Psoriasis Vulgaris |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-08-10 |
| Primary Completion | 2026-08-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2025-08-10 with a primary completion date of 2026-08-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Psoriasis is a common immune-mediated inflammatory skin disease affecting at least 100 million individuals worldwide. In Egypt, the prevalence of psoriasis ranges between 0.19% and 3% of the Egyptian people. It is associated with poor quality of life, reduced life expectancy and multimorbidity including psoriatic arthritis, obesity and cardiovascular disease. Vaspin (VASP, SERPIN 12) is a recently discovered adipokine that has been isolated from the visceral adipose tissue of a rat model of type 2 diabetes. It is coded by the gene SERPNA12 located on the long arm of chromosome 14q32.13 and consists of six exons and five introns.
Eligibility Criteria
Inclusion Criteria: * Newly diagnosed cases or stopped treatment of at least 6 months of psoriasis patients. * Pateints with any age and gender. Exclusion Criteria: * Pregnancy and lactation. * Patients with chronic diseases: cardiac diseases, hepatic disorders, chronic renal failure or malignancies. * Patients with associated inflammatory disease such as infections and autoimmune diseases.
Contact & Investigator
Moustafa Adam Ali El Taieb, Professor
STUDY CHAIR
Dermatology, Venereology and Andrology.Faculty of Medicine, Aswan University
Frequently Asked Questions
Who can join the NCT07320872 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 50 Years, studying Psoriasis Vulgaris. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07320872 currently recruiting?
Yes, NCT07320872 is actively recruiting participants. Contact the research team at olaelqousy@gmail.com for enrollment information.
Where is the NCT07320872 trial being conducted?
This trial is being conducted at Aswān, Egypt.
Who is sponsoring the NCT07320872 clinical trial?
NCT07320872 is sponsored by Aswan University. The principal investigator is Moustafa Adam Ali El Taieb, Professor at Dermatology, Venereology and Andrology.Faculty of Medicine, Aswan University. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.